The marijuana compound cannabidivarin (CBDV) has therapeutic potential for preventing neurobehavioral alterations associated with Fragile X syndrome, according to new research.

Cannabidivarin.
The research is published in the peer-reviewed journal Cells, with the title Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome. The study was conducted by researchers at the University of Brescia in Italy, SUNY Downstate Medical Center in New York City, the University of Bordeaux in France and Jazz Pharmaceuticals in the UK.
“Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs)”, states the study’s abstract. “Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remains unexplored. ”
Continue reading